RecruitingPhase 1NCT05808634
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients With Advanced Adenocarcinoma
Sponsor
BioAtla, Inc.
Enrollment
168 participants
Start Date
Jul 14, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma
- Age ≥ 18 years
- Adequate renal function
- Adequate liver function
- Adequate hematological function
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria7
- Patients must not have clinically significant cardiac disease.
- Patients must not have known non-controlled CNS metastasis.
- Patients must not have active autoimmune disease or a documented history of autoimmune disease.
- Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
- Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.
- Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
- Patients must not be women who are pregnant or breast feeding.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBA3182
Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05808634